- Aardvark prematurely terminated the Phase 3 HERO trial and is reporting only exploratory data following a clinical hold. Clinical activities for ARD-101 are not scheduled to resume until 2027, represe
?? Negative AI Sentiment (-6.5 / 10)
Observed market reaction after signal
4h -56.33% · 24h -64.81% · Peak +56.33%